A Pilot Trial of One-Day Accelerated TMS and D-cycloserine in Suicidal Patients With Borderline Personality Disorder

Part of paid clinical trials in Belmont, Massachusetts.

Sponsor
Mclean Hospital
Study ID
NCT07460947
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Borderline Personality Disorder (BPD)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • TMS — DEVICE
    TMS will consist of 600 pulses of intermittent theta burst stimulation (iTBS), with 3-minute treatment sessions delivered up to 20 times every 30 minutes for a 12-hour protocol.
  • D-Cycloserine (DCS) — DRUG
    Participants will be asked to take a single dose (250mg) of D-cycloserine the night before the treatment day.

Study Details

This study tests a new treatment for people with borderline personality disorder (BPD). The treatment combines a medication called D-cycloserine with one day of transcranial magnetic stimulation (TMS). The main questions it aims to answer are: * How many participants complete the treatment? * How do participants feel about the treatment? * Does the treatment have neurophysiological changes on participants? * Does the treatment improve BPD symptoms? * Do the benefits last over time? Participants will be asked to: * Come to the clinic for interviews and testing * Complete weekly questionnaires for 4 weeks before the treatment day * Take D-cycloserine the night before treatment * Attend one treatment day at the clinic. On that day, they may receive up to 20 short TMS sessions (each lasting 3 minutes and separated by 30 minutes). This visit may last up to 12 hours. * Complete weekly questionnaires for 6 weeks after the treatment day.

Key Dates

Start date
Jun 9, 2026
Status verified
Jun 2026
Primary completion
Jun 30, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: TMS + D-cycloserine
    Open-label combination of TMS and D-cycloserine

Primary Outcome Measure

Acceptability of Intervention Measure (AIM) [ Time Frame: Week 5 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
McLean HospitalBelmontMassachusetts02478
Alexandra L Velev, BA
[email protected]
Molly Coyle, BS
[email protected]
Joshua C Brown, MD PhD (SUB_INVESTIGATOR)
Jenna M Traynor, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Belmont, MA

By research site
McLean Hospital· Belmont, MA

Related Studies